Identification of defective illegitimate recombinational repair of oxidatively-induced DNA double-strand breaks in ataxia-telangiectasia cells.
Ataxia-telangiectasia (A-T) is an autosomal-recessive lethal human disease. Homozygotes suffer from a number of neurological disorders, as well as very high cancer incidence. Heterozygotes may also have a higher than normal risk of cancer, particularly for the breast. The gene responsible for the disease (ATM) has been cloned, but its role in mechanisms of the disease remain unknown. Cellular A-T phenotypes, such as radiosensitivity and genomic instability, suggest that a deficiency in the repair of DNA double-strand breaks (DSBs) may be the primary defect; however, overall levels of DSB rejoining appear normal. We used the shuttle vector, pZ189, containing an oxidatively-induced DSB, to compare the integrity of DSB rejoining in one normal and two A-T fibroblast cells lines. Mutation frequencies were two-fold higher in A-T cells, and the mutational spectrum was different. The majority of the mutations found in all three cell lines were deletions (44-63%). The DNA sequence analysis indicated that 17 of the 17 plasmids with deletion mutations in normal cells occurred between short direct-repeat sequences (removing one of the repeats plus the intervening sequences), implicating illegitimate recombination in DSB rejoining. The combined data from both A-T cell lines showed that 21 of 24 deletions did not involve direct-repeats sequences, implicating a defect in the illegitimate recombination pathway. These findings suggest that the A-T gene product may either directly participate in illegitimate recombination or modulate the pathway. Regardless, this defect is likely to be important to a mechanistic understanding of this lethal disease.
Dar
M E
ME
Department of Radiation Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, D.C. 20007-2197, USA.
Winters
T A
TA
Jorgensen
T J
TJ
D001260:Ataxia Telangiectasia / Q000235:genetics*; D001483:Base Sequence; D001761:Bleomycin / Q000633:toxicity; D002461:Cell Line, Transformed; D004247:DNA / Q000187:drug effects / Q000235:genetics*; D004260:DNA Repair; D005347:Fibroblasts; D015321:Gene Rearrangement; D016153:Genes, Suppressor; D005822:Genetic Vectors / Q000187:drug effects; D006801:Humans; D008969:Molecular Sequence Data; D016296:Mutagenesis; D010084:Oxidation-Reduction; D012343:RNA, Transfer / Q000235:genetics; D011995:Recombination, Genetic
C096275:supF tRNA; D001761:Bleomycin; D004247:DNA; D012343:RNA, Transfer